In our previous work, we showed that truncating mutations, but not missense mutations, in the CHEK2 gene are significantly associated with angioinvasion and an intermediate or high initial risk of recurrent/persistent disease in PTC patients [21]; however, we did not evaluate CHK2 and p53 expression in tumor tissues. This evidence concerns the gene CHEK2 and neoplasm.